Investors Urged to Join Skye Bioscience Securities Fraud Class Action Lawsuit

Introduction
The Schall Law Firm, renowned for advocating shareholders' rights, is leading the charge in a class-action lawsuit against Skye Bioscience, Inc. This legal battle has arisen from serious allegations of securities fraud, concerning misleading information disseminated by the company regarding its clinical prospects and a key drug candidate.

Background on Skye Bioscience, Inc.
Skye Bioscience (NASDAQ: SKYE) is a company focused on developing innovative treatments leveraging its proprietary cannabinoid technology. Investors were enthusiastic about the company's leading drug candidate, nimacimab, touted as a breakthrough therapy. However, recent developments suggest that the expectations set by Skye may have been well beyond realistic outcomes.

Details of the Class Action Lawsuit
The lawsuit specifically addresses violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5, which aims to deter deceptive practices in securities trading. The investors who acquired Skye's securities from November 4, 2024, to October 3, 2025, are encouraged to come forward by the stated deadline of January 16, 2026.

The Schall Law Firm emphasizes that potential plaintiffs should reach out for assistance, as the class has yet to receive formal certification. Until that happens, investors remain unrepresented in the case. For any investor who incurred a loss during this period, there is a pathway to possibly recover those losses.

Allegations Against Skye Bioscience
According to the filed Complaint, Skye Bioscience made several false and misleading statements that artificially inflated the company's stock price. Although the company claimed that nimacimab would yield significant results in their clinical studies, emerging evidence disclosed that the drug's efficacy was inferior to what Skye had reported. This disparity between the touted benefits of nimacimab and its actual performance has materially misled investors, leading to financial damage when the truth was revealed.

Role of The Schall Law Firm
As a key player in this case, The Schall Law Firm has built a reputation for providing trustworthy guidance and legal representation to investors facing challenges of this nature. By acting swiftly, they aim to facilitate participation for those harmed by corporate misrepresentations. Investors can easily reach out to the firm by calling Brian Schall at 310-301-3335, visiting their website at www.schallfirm.com, or through email for consultations without charge.

Conclusion
As the landscape of biotech investments fluctuates, the risk of securities fraud is a pressing concern for many shareholders. The Schall Law Firm stands ready to challenge such unethical practices, ensuring that investors like those in Skye Bioscience have their voices heard and rights upheld. If you are among those who invested during the class period, joining the lawsuit could help reclaim your financial footing.